Klimadynon Tablets (Cimicifugae Rhizome Extract 20 mg): Indications, Dosage, and Patient Information Leaflet

Medically Reviewed by: Dr. Ahmed Abdulbaqi | Consult our Editorial Policy.

Executive Clinical Summary

Klimadynon is a standardized herbal pharmaceutical formulated as film-coated tablets, containing 20 mg dry extract preparation of Cimicifugae racemosae rhizome per unit. It is indicated for neurovegetative and psychic complaints occurring prior to and during menopause, notably hot flushes, profuse sweating, insomnia, nervousness, and depressive moods.

Active Composition

  • Active Ingredient: Dry extract of Cimicifugae rhizome.
  • Strength: 1 film-coated tablet contains 20 mg dry extract preparation of Cimicifugae racemosae rhizome.

Therapeutic Indications

  • Climacteric complaints during menopause, including hot flushes and sweating.
  • Disturbed sleep, emotional nervousness, and depressive emotional states.
  • Neurovegetative and psychic complaints preceding the onset of menopause.

Dosage and Administration

  • Standard Dosage: Take 1 film-coated tablet twice daily (mornings and evenings), unless otherwise directed by a healthcare professional.
  • Duration of Use: Klimadynon should not be taken for a period exceeding 6 months without consulting a physician.

Critical Safety Information & Contraindications

  • Absolute Contraindication: Do not use in cases of oestrogen-dependent tumours.
  • Adverse Reactions: Occasionally, gastric complaints and weight gain are possible.

Storage Conditions & Manufacturing

  • Store in a dry, cool place.
  • Keep out of reach of children.
  • Manufacturer: BIONORICA AG, Kerschensteinerstr. 11-15, 92318 Neumarkt, Germany.
  • Sole Agent (Egypt): Technomad Group, 9 El Nashat St., Nasr City, Cairo.

Document Preview

References & Regulatory Sources:

  1. Klimadynon Film-Coated Tablets, Patient Information Leaflet. Bionorica AG, Neumarkt, Germany.
  2. European Medicines Agency (EMA) Committee on Herbal Medicinal Products (HMPC). European Union herbal monograph on Cimicifuga racemosa (L.) Nutt., rhizoma.
  3. World Health Organization (WHO). WHO Monographs on Selected Medicinal Plants - Volume 2: Rhizoma Cimicifugae Racemosae.
Disclaimer: This content is published strictly for informational, educational, and reference purposes. It does not constitute individual clinical advice, medical diagnosis, or treatment prescription. Always consult a qualified physician or pharmacist prior to commencing any medication or herbal therapy. Read our full Medical Disclaimer.
 
   
     

About the Author

     

Dr. Ahmad Baker, PharmD

     

He is a senior pharmacist and health educator with extensive experience in the Middle East and North Africa region. Through his writing, Dr. Ahmad aims to empower communities by providing reliable, evidence-based health information. With expertise in clinical pharmacy and regulatory affairs, he strives to offer unique insights into healthcare and simplify complex medical concepts, making them accessible to everyone.

   
   
      Dr. Ahmad Baker    
 
      
   

Legal Disclaimer

   

The information provided in this blog is for educational purposes only and is not a substitute for professional medical advice. We do not guarantee the accuracy or completeness of information regarding medications or medical products, and official sources should be verified before making any decisions. By using this blog, you agree to assume personal responsibility for relying on the information provided.

 

Comments

Popular posts from this blog

Epimag: Uses, Benefits, and Side Effects Explained

Understanding EPIMAG: Uses, Precautions, and More

Understanding Coli-Urinal Effervescent Granules: A Guide for Urinary Health